SIRT1 Regulates Sphingolipid Metabolism and Neural

Total Page:16

File Type:pdf, Size:1020Kb

SIRT1 Regulates Sphingolipid Metabolism and Neural bioRxiv preprint doi: https://doi.org/10.1101/2021.02.24.432815; this version posted February 25, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. 1 SIRT1 regulates sphingolipid metabolism and neural 2 differentiation of mouse embryonic stem cells through c-Myc- 3 SMPDL3B 4 5 Wei Fan,1 Shuang Tang, 1, 6 Xiaojuan Fan, 2 Yi Fang,1 Xiaojiang Xu, 3 Leping Li, 4 Jian Xu, 6 5 Jian-Liang Li, 3 Zefeng Wang, 2, * and Xiaoling Li 1, * 7 8 1Signal Transduction Laboratory, National Institute of Environmental Health Sciences, 9 Research Triangle Park, NC 27709, USA 10 2CAS Key Laboratory of Computational Biology, CAS-MPG Partner Institute for 11 Computational Biology, Shanghai Institute of Nutrition and Health, Shanghai Institutes for 12 Biological Sciences, University of Chinese Academy of Sciences, CAS Center for 13 Excellence in Molecular Cell Science, Chinese Academy of Sciences, Shanghai 200031, 14 China 15 3Integrative Bioinformatics Support Group, National Institute of Environmental Health 16 Sciences, Research Triangle Park, NC 27709, USA 17 4Biostatistics & Computational Biology Branch, National Institute of Environmental Health 18 Sciences, Research Triangle Park, NC 27709, USA 19 5Children's Medical Center Research Institute, Department of Pediatrics, Harold C. 20 Simmons Comprehensive Cancer Center, and Hamon Center for Regenerative Science 21 and Medicine, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA. 22 6Current address: Cancer Institute and Department of Nuclear Medicine, Fudan University 23 Shanghai Cancer Center, Shanghai 200032, China 24 25 1 bioRxiv preprint doi: https://doi.org/10.1101/2021.02.24.432815; this version posted February 25, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. 26 * Correspondence: [email protected] (X. L.), [email protected] (Z. W.) 27 Short title: SIRT1 regulates sphingolipid metabolism 28 Key words: SIRT1; sphingomyelin degradation; embryonic stem cells; neural development; 29 embryogenesis; c-Myc 30 2 bioRxiv preprint doi: https://doi.org/10.1101/2021.02.24.432815; this version posted February 25, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. 31 Abstract 32 Sphingolipids are important structural components of cell membranes and 33 prominent signaling molecules controlling cell growth, differentiation, and apoptosis. 34 Sphingolipids are particularly abundant in the brain, and defects in sphingolipid 35 degradation are associated with several human neurodegenerative diseases. However, 36 molecular mechanisms governing sphingolipid metabolism remain unclear. Here we 37 report that sphingolipid degradation is under transcriptional control of SIRT1, a highly 38 conserved mammalian NAD+-dependent protein deacetylase, in mouse embryonic stem 39 cells (mESCs). Deletion of SIRT1 results in accumulation of sphingomyelin in mESCs, 40 primarily due to reduction of SMPDL3B, a GPI-anchored plasma membrane bound 41 sphingomyelin phosphodiesterase. Mechanistically, SIRT1 regulates transcription of 42 Smpdl3b through c-Myc. Functionally, SIRT1 deficiency-induced accumulation of 43 sphingomyelin increases membrane fluidity and impairs neural differentiation in vitro and 44 in vivo. Our findings discover a key regulatory mechanism for sphingolipid homeostasis 45 and neural differentiation, further imply that pharmacological manipulation of SIRT1- 46 mediated sphingomyelin degradation might be beneficial for treatment of human 47 neurological diseases. 48 49 50 51 3 bioRxiv preprint doi: https://doi.org/10.1101/2021.02.24.432815; this version posted February 25, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. 52 Introduction 53 First isolated from brain extract in the 1880s, sphingolipid is a class of natural lipids 54 containing a backbone of sphingoid base sphingosine (1-3). Sphingolipids not only are the 55 structural components of cell membranes, but also act as signaling molecules to control 56 various cellular events, including signal transduction, cell growth, differentiation, and 57 apoptosis (4, 5). Particularly, sphingolipids are enriched in microdomains/lipid rafts, a 58 liquid-ordered phase in plasma membrane, where sphingomyelin, glycosphingolipids and 59 cholesterol form unique platforms for many different proteins that are important for nutrient 60 transport, organelle contact, membrane trafficking, and homotypic fusion (6). 61 The homeostasis of sphingolipids is maintained by a highly coordinated metabolic 62 network that links together various pathways with ceramide as a central node (Figure S1A). 63 Firstly, ceramide can be de novo synthesized in endoplasmic reticulum (ER), starting from 64 the condensation of serine and fatty acyl-CoA by serine palmitoyltransferase (SPT). 65 Ceramide is then transported to the Golgi complex and further converted into more 66 complex forms of sphingolipids, such as glycosphingolipids or sphingomyelin. Secondly, 67 ceramide can be regenerated by hydrolysis of complex sphingolipids in the Golgi complex 68 and plasma membrane, which is catalyzed by a class of specific hydrolases and 69 phosphodiesterases. For example, regeneration of ceramide from sphingomyelin can be 70 mediated by plasma membrane bound sphingomyelin phosphodiesterases (SMPDs), 71 including SMPDL3B, a GPI-anchored lipid raft SMPD (7). By degrading sphingomyelin, 72 SMPDL3B regulates plasma membrane fluidity, which in turn impacts TLR-mediated 73 innate immunity in macrophages (7) and modulates insulin receptor signaling in podocytes 74 (8). Sphingolipid metabolism is highly sensitive to environmental/nutritional perturbations. 75 Sphingolipid biosynthesis and accumulation can be induced by high-fat diet (HFD) feeding 76 in multiple tissues in mice (9). Sphingolipids are also accumulated during aging (10, 11), 77 and caloric restriction, a dietary regimen known to extend life span and delay a number of 4 bioRxiv preprint doi: https://doi.org/10.1101/2021.02.24.432815; this version posted February 25, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. 78 age-associated diseases, decreases sphingolipid accumulation by reducing the activity of 79 SPT (12). Dietary serine restriction also alters sphingolipid diversity and synthesis to 80 constrain tumor growth (13). 81 Disruption of sphingolipid homeostasis has been involved in the pathogenesis of 82 a number of human diseases, such as Niemann-Pick disease and neurodegenerative 83 Alzheimer’s, Parkinson’s, and Huntington’s diseases. These human diseases are 84 generally the outcome of defect in enzymes that degrade the sphingolipids (14, 15). Such 85 degradation defect leads to accumulation of sphingolipids, which in turn dramatically alters 86 cellular membrane structure and signaling, thereby triggering various diseases. 87 Consequently, manipulation of one enzyme or metabolite in sphingolipid degradation 88 pathways may result in unexpected changes in cellular metabolic programs and related 89 cellular functions (14, 15). However, molecular mechanisms that regulate the expression 90 of these sphingolipid degrading enzymes remain unclear. 91 In the present study, we investigated the role of SIRT1 in regulation of sphingolipid 92 degradation in mouse embryonic stem cells (mESCs) and mouse embryos. SIRT1 is a 93 NAD+-dependent protein deacetylase critical for multiple cellular processes, including 94 metabolism, inflammation, stress response, and stem cell functions (16-18). SIRT1 is also 95 a key regulator of animal development (19-21), and is particularly important in the central 96 nervous system. For instance, SIRT1 has a major influence on hypothalamic function, and 97 cell-type specific SIRT1 mutations result in defects in systemic energy metabolism, 98 circadian rhythm, and the lifespan of the animal (22-25). SIRT1 also modulates dendritic 99 and axonal growth (26, 27), and regulates synaptic plasticity and memory formation in 100 adult brain (28). Moreover, SIRT1 has been shown to ameliorate neurodegenerative 101 phenotypes in animal models of Alzheimer’s, Parkinson’s, and Huntington’s disease 102 (reviewed in (29)). However, despite multiple mechanisms proposed for these critical roles 103 of SIRT1 in the brain, how SIRT1 regulates neural development and function remain 5 bioRxiv preprint doi: https://doi.org/10.1101/2021.02.24.432815; this version posted February 25, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. 104 unclear. Through global metabolomics and cellular
Recommended publications
  • Sphingolipid Metabolism Diseases ⁎ Thomas Kolter, Konrad Sandhoff
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Biochimica et Biophysica Acta 1758 (2006) 2057–2079 www.elsevier.com/locate/bbamem Review Sphingolipid metabolism diseases ⁎ Thomas Kolter, Konrad Sandhoff Kekulé-Institut für Organische Chemie und Biochemie der Universität, Gerhard-Domagk-Str. 1, D-53121 Bonn, Germany Received 23 December 2005; received in revised form 26 April 2006; accepted 23 May 2006 Available online 14 June 2006 Abstract Human diseases caused by alterations in the metabolism of sphingolipids or glycosphingolipids are mainly disorders of the degradation of these compounds. The sphingolipidoses are a group of monogenic inherited diseases caused by defects in the system of lysosomal sphingolipid degradation, with subsequent accumulation of non-degradable storage material in one or more organs. Most sphingolipidoses are associated with high mortality. Both, the ratio of substrate influx into the lysosomes and the reduced degradative capacity can be addressed by therapeutic approaches. In addition to symptomatic treatments, the current strategies for restoration of the reduced substrate degradation within the lysosome are enzyme replacement therapy (ERT), cell-mediated therapy (CMT) including bone marrow transplantation (BMT) and cell-mediated “cross correction”, gene therapy, and enzyme-enhancement therapy with chemical chaperones. The reduction of substrate influx into the lysosomes can be achieved by substrate reduction therapy. Patients suffering from the attenuated form (type 1) of Gaucher disease and from Fabry disease have been successfully treated with ERT. © 2006 Elsevier B.V. All rights reserved. Keywords: Ceramide; Lysosomal storage disease; Saposin; Sphingolipidose Contents 1. Sphingolipid structure, function and biosynthesis ..........................................2058 1.1.
    [Show full text]
  • 743914V1.Full.Pdf
    bioRxiv preprint doi: https://doi.org/10.1101/743914; this version posted August 24, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 1 Cross-talks of glycosylphosphatidylinositol biosynthesis with glycosphingolipid biosynthesis 2 and ER-associated degradation 3 4 Yicheng Wang1,2, Yusuke Maeda1, Yishi Liu3, Yoko Takada2, Akinori Ninomiya1, Tetsuya 5 Hirata1,2,4, Morihisa Fujita3, Yoshiko Murakami1,2, Taroh Kinoshita1,2,* 6 7 1Research Institute for Microbial Diseases, Osaka University, Suita, Osaka 565-0871, Japan 8 2WPI Immunology Frontier Research Center, Osaka University, Suita, Osaka 565-0871, 9 Japan 10 3Key Laboratory of Carbohydrate Chemistry and Biotechnology, Ministry of Education, 11 School of Biotechnology, Jiangnan University, Wuxi, Jiangsu 214122, China 12 4Current address: Center for Highly Advanced Integration of Nano and Life Sciences (G- 13 CHAIN), Gifu University, 1-1 Yanagido, Gifu-City, Gifu 501-1193, Japan 14 15 *Correspondence and requests for materials should be addressed to T.K. (email: 16 [email protected]) 17 18 19 Glycosylphosphatidylinositol (GPI)-anchored proteins and glycosphingolipids interact with 20 each other in the mammalian plasma membranes, forming dynamic microdomains. How their 21 interaction starts in the cells has been unclear. Here, based on a genome-wide CRISPR-Cas9 22 genetic screen for genes required for GPI side-chain modification by galactose in the Golgi 23 apparatus, we report that b1,3-galactosyltransferase 4 (B3GALT4), also called GM1 24 ganglioside synthase, additionally functions in transferring galactose to the N- 25 acetylgalactosamine side-chain of GPI.
    [Show full text]
  • Cholesterol-Dependent Increases in Glucosylceramide
    Neuropharmacology 110 (2016) 458e469 Contents lists available at ScienceDirect Neuropharmacology journal homepage: www.elsevier.com/locate/neuropharm Cholesterol-dependent increases in glucosylceramide synthase activity in Niemann-Pick disease type C model cells: Abnormal trafficking of endogenously formed ceramide metabolites by inhibition of the enzyme Naohiro Hashimoto 1, Ikiru Matsumoto 1, Hiromasa Takahashi, Hitomi Ashikawa, * Hiroyuki Nakamura , Toshihiko Murayama Laboratory of Chemical Pharmacology, Graduate School of Pharmaceutical Sciences, Chiba University, Chiba 260-8675, Japan article info abstract Article history: Sphingolipids such as sphingomyelin and glycosphingolipids (GSLs) derived from glucosylceramide Received 1 February 2016 (GlcCer), in addition to cholesterol, accumulate in cells/neurons in Niemann-Pick disease type C (NPC). Received in revised form The activities of acid sphingomyelinase and lysosomal glucocerebrosidase (GCase), which degrade 10 August 2016 sphingomyelin and GlcCer, respectively, are down-regulated in NPC cells, however, changes in GlcCer Accepted 12 August 2016 synthase activity have not yet been elucidated. We herein demonstrated for the first time that GlcCer Available online 15 August 2016 synthase activity for the fluorescent ceramide, 4-nitrobenzo-2-oxa-1,3-diazole-labeled C6-ceramide À À (NBD-ceramide) increased in intact NPC1( / ) cells and cell lysates without affecting the protein levels. Keywords: (À/À) fl Niemann-Pick disease type C In NBD-ceramide-labeled NPC1 cells, NBD- uorescence preferentially accumulated in the Golgi Cholesterol complex and vesicular specks in the cytoplasm 40 and 150 min, respectively, after labeling, while a Glucosylceramide synthase treatment for 48 h with the GlcCer synthase inhibitors, N-butyldeoxynojirimycin (NB-DNJ) and 1-phenyl- Sphingomyelin 2-palmitoylamino-3-morpholino-1-propanol, accelerated the appearance of vesicular specks emitting À À Vesicular trafficking NBD-fluorescence within 40 min.
    [Show full text]
  • Supplementary Methods
    Supplementary methods Human lung tissues and tissue microarray (TMA) All human tissues were obtained from the Lung Cancer Specialized Program of Research Excellence (SPORE) Tissue Bank at the M.D. Anderson Cancer Center (Houston, TX). A collection of 26 lung adenocarcinomas and 24 non-tumoral paired tissues were snap-frozen and preserved in liquid nitrogen for total RNA extraction. For each tissue sample, the percentage of malignant tissue was calculated and the cellular composition of specimens was determined by histological examination (I.I.W.) following Hematoxylin-Eosin (H&E) staining. All malignant samples retained contained more than 50% tumor cells. Specimens resected from NSCLC stages I-IV patients who had no prior chemotherapy or radiotherapy were used for TMA analysis by immunohistochemistry. Patients who had smoked at least 100 cigarettes in their lifetime were defined as smokers. Samples were fixed in formalin, embedded in paraffin, stained with H&E, and reviewed by an experienced pathologist (I.I.W.). The 413 tissue specimens collected from 283 patients included 62 normal bronchial epithelia, 61 bronchial hyperplasias (Hyp), 15 squamous metaplasias (SqM), 9 squamous dysplasias (Dys), 26 carcinomas in situ (CIS), as well as 98 squamous cell carcinomas (SCC) and 141 adenocarcinomas. Normal bronchial epithelia, hyperplasia, squamous metaplasia, dysplasia, CIS, and SCC were considered to represent different steps in the development of SCCs. All tumors and lesions were classified according to the World Health Organization (WHO) 2004 criteria. The TMAs were prepared with a manual tissue arrayer (Advanced Tissue Arrayer ATA100, Chemicon International, Temecula, CA) using 1-mm-diameter cores in triplicate for tumors and 1.5 to 2-mm cores for normal epithelial and premalignant lesions.
    [Show full text]
  • PFK-2/Fbpase-2: Maker and Breaker of the Essential Biofactor Fructose-2, 6-Bisphosphate
    30 Review TRENDS in Biochemical Sciences Vol.26 No.1 January 2001 PFK-2/FBPase-2: maker and breaker of the essential biofactor fructose-2, 6-bisphosphate DavidA. Okar, Ànna Manzano,Aurèa Navarro-Sabatè, Lluìs Riera, Ramon Bartrons and Alex J. Lange Fructose-2,6-bisphosphate is responsible for mediating glucagon-stimulated extraction in base led to the discovery of F-2,6-P2 and gluconeogenesis in the liver.This discovery has led to the realization that this the realization that it was either formed or destroyed compound plays a significant role in directing carbohydrate fluxes in all during metabolic transitions where its concentration eukaryotes. Biophysical studies of the enzyme that both synthesizes and determined changes in glycolytic and gluconeogenic degrades this biofactor have yielded insight into its molecular enzymology. carbon flux in the liver. Interest in this compound grew Moreover, the metabolic role of fructose-2,6-bisphosphate has great potential rapidly because it was found to be a most potent in the treatment of diabetes. positive allosteric effector of 6-phosphofructo-1- kinase (PFK-1; EC 2.7.1.11) and an inhibitor of A trail that began with the discovery of a highly potent fructose-1,6-bisphosphatase (FBPase-1; EC 3.1.3.11). regulator of mammalian hepatic carbohydrate Because of its antagonistic actions on these enzymes, metabolism, fructose-2,6-bisphosphate (F-2,6-P2), led F-2,6-P2 plays a crucial role in the control of the to the discovery of the bifunctional enzyme opposing hepatic glycolytic and gluconeogenic 6-phosphofructo-2-kinase/fructose- pathways1–4 (Fig.
    [Show full text]
  • Targeting the Sphingosine Kinase/Sphingosine-1-Phosphate Signaling Axis in Drug Discovery for Cancer Therapy
    cancers Review Targeting the Sphingosine Kinase/Sphingosine-1-Phosphate Signaling Axis in Drug Discovery for Cancer Therapy Preeti Gupta 1, Aaliya Taiyab 1 , Afzal Hussain 2, Mohamed F. Alajmi 2, Asimul Islam 1 and Md. Imtaiyaz Hassan 1,* 1 Centre for Interdisciplinary Research in Basic Sciences, Jamia Millia Islamia, Jamia Nagar, New Delhi 110025, India; [email protected] (P.G.); [email protected] (A.T.); [email protected] (A.I.) 2 Department of Pharmacognosy, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia; afi[email protected] (A.H.); [email protected] (M.F.A.) * Correspondence: [email protected] Simple Summary: Cancer is the prime cause of death globally. The altered stimulation of signaling pathways controlled by human kinases has often been observed in various human malignancies. The over-expression of SphK1 (a lipid kinase) and its metabolite S1P have been observed in various types of cancer and metabolic disorders, making it a potential therapeutic target. Here, we discuss the sphingolipid metabolism along with the critical enzymes involved in the pathway. The review provides comprehensive details of SphK isoforms, including their functional role, activation, and involvement in various human malignancies. An overview of different SphK inhibitors at different phases of clinical trials and can potentially be utilized as cancer therapeutics has also been reviewed. Citation: Gupta, P.; Taiyab, A.; Hussain, A.; Alajmi, M.F.; Islam, A.; Abstract: Sphingolipid metabolites have emerged as critical players in the regulation of various Hassan, M..I. Targeting the Sphingosine Kinase/Sphingosine- physiological processes. Ceramide and sphingosine induce cell growth arrest and apoptosis, whereas 1-Phosphate Signaling Axis in Drug sphingosine-1-phosphate (S1P) promotes cell proliferation and survival.
    [Show full text]
  • Structural Study of the Acid Sphingomyelinase Protein Family
    Structural Study of the Acid Sphingomyelinase Protein Family Alexei Gorelik Department of Biochemistry McGill University, Montreal August 2017 A thesis submitted to McGill University in partial fulfillment of the requirements of the degree of Doctor of Philosophy © Alexei Gorelik, 2017 Abstract The acid sphingomyelinase (ASMase) converts the lipid sphingomyelin (SM) to ceramide. This protein participates in lysosomal lipid metabolism and plays an additional role in signal transduction at the cell surface by cleaving the abundant SM to ceramide, thus modulating membrane properties. These functions are enabled by the enzyme’s lipid- and membrane- interacting saposin domain. ASMase is part of a small family along with the poorly characterized ASMase-like phosphodiesterases 3A and 3B (SMPDL3A,B). SMPDL3A does not hydrolyze SM but degrades extracellular nucleotides, and is potentially involved in purinergic signaling. SMPDL3B is a regulator of the innate immune response and podocyte function, and displays a partially defined lipid- and membrane-modifying activity. I carried out structural studies to gain insight into substrate recognition and molecular functions of the ASMase family of proteins. Crystal structures of SMPDL3A uncovered the helical fold of a novel C-terminal subdomain, a slightly distinct catalytic mechanism, and a nucleotide-binding mode without specific contacts to their nucleoside moiety. The ASMase investigation revealed a conformational flexibility of its saposin domain: this module can switch from a detached, closed conformation to an open form which establishes a hydrophobic interface to the catalytic domain. This open configuration represents the active form of the enzyme, likely allowing lipid access to the active site. The SMPDL3B structure showed a narrow, boot-shaped substrate binding site that accommodates the head group of SM.
    [Show full text]
  • Integration of Lipidomics and Transcriptomics Data Towards A
    Gupta et al. BMC Systems Biology 2011, 5:26 http://www.biomedcentral.com/1752-0509/5/26 RESEARCHARTICLE Open Access Integration of lipidomics and transcriptomics data towards a systems biology model of sphingolipid metabolism Shakti Gupta1, Mano R Maurya1, Alfred H Merrill Jr2, Christopher K Glass3, Shankar Subramaniam1,3,4* Abstract Background: Sphingolipids play important roles in cell structure and function as well as in the pathophysiology of many diseases. Many of the intermediates of sphingolipid biosynthesis are highly bioactive and sometimes have antagonistic activities, for example, ceramide promotes apoptosis whereas sphingosine-1-phosphate can inhibit apoptosis and induce cell growth; therefore, quantification of the metabolites and modeling of the sphingolipid network is imperative for an understanding of sphingolipid biology. Results: In this direction, the LIPID MAPS Consortium is developing methods to quantitate the sphingolipid metabolites in mammalian cells and is investigating their application to studies of the activation of the RAW264.7 macrophage cell by a chemically defined endotoxin, Kdo2-Lipid A. Herein, we describe a model for the C16-branch of sphingolipid metabolism (i.e., for ceramides with palmitate as the N-acyl-linked fatty acid, which is selected because it is a major subspecies for all categories of complex sphingolipids in RAW264.7 cells) integrating lipidomics and transcriptomics data and using a two-step matrix-based approach to estimate the rate constants from experimental data. The rate constants obtained from the first step are further refined using generalized constrained nonlinear optimization. The resulting model fits the experimental data for all species. The robustness of the model is validated through parametric sensitivity analysis.
    [Show full text]
  • Human Induced Pluripotent Stem Cell–Derived Podocytes Mature Into Vascularized Glomeruli Upon Experimental Transplantation
    BASIC RESEARCH www.jasn.org Human Induced Pluripotent Stem Cell–Derived Podocytes Mature into Vascularized Glomeruli upon Experimental Transplantation † Sazia Sharmin,* Atsuhiro Taguchi,* Yusuke Kaku,* Yasuhiro Yoshimura,* Tomoko Ohmori,* ‡ † ‡ Tetsushi Sakuma, Masashi Mukoyama, Takashi Yamamoto, Hidetake Kurihara,§ and | Ryuichi Nishinakamura* *Department of Kidney Development, Institute of Molecular Embryology and Genetics, and †Department of Nephrology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan; ‡Department of Mathematical and Life Sciences, Graduate School of Science, Hiroshima University, Hiroshima, Japan; §Division of Anatomy, Juntendo University School of Medicine, Tokyo, Japan; and |Japan Science and Technology Agency, CREST, Kumamoto, Japan ABSTRACT Glomerular podocytes express proteins, such as nephrin, that constitute the slit diaphragm, thereby contributing to the filtration process in the kidney. Glomerular development has been analyzed mainly in mice, whereas analysis of human kidney development has been minimal because of limited access to embryonic kidneys. We previously reported the induction of three-dimensional primordial glomeruli from human induced pluripotent stem (iPS) cells. Here, using transcription activator–like effector nuclease-mediated homologous recombination, we generated human iPS cell lines that express green fluorescent protein (GFP) in the NPHS1 locus, which encodes nephrin, and we show that GFP expression facilitated accurate visualization of nephrin-positive podocyte formation in
    [Show full text]
  • The Role of Triacylglycerol in Plant Stress Response
    plants Review The Role of Triacylglycerol in Plant Stress Response Junhao Lu 1, Yang Xu 1, Juli Wang 1, Stacy D. Singer 2,* and Guanqun Chen 1,* 1 Department of Agricultural, Food and Nutritional Science, University of Alberta, Edmonton, T6G 2P5 Alberta, Canada; [email protected] (J.L.); [email protected] (Y.X.); [email protected] (J.W.) 2 Agriculture and Agri-Food Canada, Lethbridge Research and Development Centre, Lethbridge, T1J 4B1 Alberta, Canada * Correspondence: [email protected] (S.D.S.); [email protected] (G.C.); Tel.: +1-403-317-3386 (S.D.S.); +1-780-492-3148 (G.C.) Received: 4 March 2020; Accepted: 2 April 2020; Published: 8 April 2020 Abstract: Vegetable oil is mainly composed of triacylglycerol (TAG), a storage lipid that serves as a major commodity for food and industrial purposes, as well as an alternative biofuel source. While TAG is typically not produced at significant levels in vegetative tissues, emerging evidence suggests that its accumulation in such tissues may provide one mechanism by which plants cope with abiotic stress. Different types of abiotic stress induce lipid remodeling through the action of specific lipases, which results in various alterations in membrane lipid composition. This response induces the formation of toxic lipid intermediates that cause membrane damage or cell death. However, increased levels of TAG under stress conditions are believed to function, at least in part, as a means of sequestering these toxic lipid intermediates. Moreover, the lipid droplets (LDs) in which TAG is enclosed also function as a subcellular factory to provide binding sites and substrates for the biosynthesis of bioactive compounds that protect against insects and fungi.
    [Show full text]
  • Shaping the Sperm Head: an ER Enzyme Leaves Its Mark
    Shaping the sperm head: an ER enzyme leaves its mark Angshumoy Roy, … , Yi-Nan Lin, Martin M. Matzuk J Clin Invest. 2006;116(11):2860-2863. https://doi.org/10.1172/JCI30221. Commentary Lipid storage diseases are debilitating inherited metabolic disorders that stem from the absence of specific lysosomal enzymes that degrade selected lipids. Most characteristically, these disorders affect the nervous and the reticulo- endothelial systems, with massive organomegaly resulting from the presence of engorged, lipid-laden macrophages. In this issue of the JCI, Yildiz et al. describe the role of the ER-resident enzyme β-glucosidase 2 (GBA2) in mice (see the related article beginning on page 2985). Surprisingly, GBA2 deficiency leaves bile acid and cholesterol metabolism intact, instead causing lipid accumulation in the ER of testicular Sertoli cells, round-headed sperm (globozoospermia), and impaired male fertility. Find the latest version: https://jci.me/30221/pdf commentaries 1. Niederkorn, J.Y. 2006. See no evil, hear no evil, do no 7. Asheuer, M., et al. 2004. Human CD34+ cells dif- 13. Nimmerjahn, A., Kirchhoff, F., and Helmchen, F. evil: the lessons of immune privilege. Nat. Immunol. ferentiate into microglia and express recombinant 2005. Resting microglial cells are highly dynamic 7:354–359. therapeutic protein. Proc. Natl. Acad. Sci. U. S. A. surveillants of brain parenchyma in vivo. Science. 2. Pardridge, W.M. 2005. The blood-brain barrier: 101:3557–3562. 308:1314–1318. bottleneck in brain drug development. NeuroRx. 8. Biffi, A., et al. 2006. Gene therapy of metachromat- 14. Matzner, U., and Gieselmann, V. 2005. Gene thera- 2:3–14.
    [Show full text]
  • The Crystal Structure of the Bifunctional Enzyme 6-Phosphofructo-2-Kinase
    Research Article 1017 The crystal structure of the bifunctional enzyme 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase reveals distinct domain homologies Charles A Hasemann†*, Eva S Istvan1, Kosaku Uyeda1,2 and Johann Deisenhofer1,3 Background: Glucose homeostasis is maintained by the processes of Addresses: 1Department of Biochemistry, glycolysis and gluconeogenesis. The importance of these pathways is University of Texas Southwestern Medical Center, demonstrated by the severe and life threatening effects observed in various 5323 Harry Hines Blvd., Dallas, TX 75235 USA, 2Research Service, Department of Veterans Affairs forms of diabetes. The bifunctional enzyme 6-phosphofructo-2-kinase/fructose- Medical Center, 4500 S. Lancaster Rd., Dallas, 2,6-bisphosphatase catalyzes both the synthesis and degradation of fructose- TX, 75216 USA and 3Howard Hughes Medical 2,6-bisphosphate, a potent regulator of glycolysis. Thus this bifunctional enzyme Institute, University of Texas, Southwestern plays an indirect yet key role in the regulation of glucose metabolism. Medical Center, 5323 Harry Hines Blvd., Dallas, TX 75235, USA. Results: We have determined the 2.0 Å crystal structure of the rat testis †Present address: Department of Internal isozyme of this bifunctional enzyme. The enzyme is a homodimer of 55 kDa Medicine, Division of Rheumatology, and the subunits arranged in a head-to-head fashion, with each monomer consisting of Harold C Simmons Center for Arthritis Research, University of Texas Southwestern Medical Center, independent kinase and phosphatase domains. The location of ATPgS and 5323 Harry Hines Blvd., Dallas, TX 75235-8884, inorganic phosphate in the kinase and phosphatase domains, respectively, allow USA. us to locate and describe the active sites of both domains.
    [Show full text]